力达霉素对肝肿瘤起始细胞表型的调控作用及机制探讨

力达霉素对肝肿瘤起始细胞表型的调控作用及机制探讨

王永民

【期刊名称】《中国卫生标准管理》 【年(卷),期】2015(000)024

【摘要】Objective To discuss lidamycin’s regulation and mechanisms of hepatoma initiating cels phenotype. MethodsUsing transplanted subcutaneously in nude tumor model to detect lidamycin’s treatment effect on Huh7 tumor-initiating cel,and reviewed the relevant mechanisms.Results Lidamycin can significantly reduce the volume of tumor and delay the occurrence of tumor .Further study showed that lidamycin's effect on possible molecular mechanism in cancer initating cels was that whether lidamycin was in vivo or in vitro,it can significantly make CSK3β / β-catenin pathway activity to reduce.Conclusion Lidamycin can inhibit Huh7 liver tumor initiating cels in vitro and vivo,lower GSK3β/β-catenin pathway’s slight status, reveal tumor-initiating

cels

inhibited

by

lidamycin

possible

molecular

mechanisms,and provide a reference for clinical trials.%目的：探讨力达霉素对肝肿瘤起始细胞表型的调控作用及机制。方法运用裸鼠皮下移植瘤模型，对力达霉素治疗肝癌Huh7肿瘤起始细胞效果展开检测，回顾相关作用机制。结果力达霉素可使肿瘤体积缩小，将肿瘤的发生时间推迟。深入研究示，力达霉素在肿瘤起始细胞作用的可能分子机制为：力达霉素在体内或体外，均可使CSK3β/β-catenin通路活性下调。结论力达霉素可在体内、体外对Huch7肝